glp-1 pediatric receptor agonists in obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety 175: Live! Small Doses, Big

Because of its low IGFBP binding, researchers have noted increased availability of free ligand to target-cell receptors in these model systems compared with native IGF-1

Cosmetics 5.3.9

Commercial Insurance: Tightening Coverage Many Plans Dropping or Restricting Coverage (Jan 2026) Effective January 1, 2026, multiple insurers have dropped or restricted GLP-1 coverage for weight loss , limiting it to type 2 diabetes or plans with explicit weight management benefits: [11] Health New England: Dropped Wegovy, Zepbound, and Saxenda coverage for individual and small group members effective January 1, 2026 Fallon Health: Community Care plans no longer cover weight loss medications as of January 1, 2026 BCBS, UnitedHealthcare, Cigna: Many plans restricting GLP-1s to type 2 diabetes only, unless employers opt for weight management riders CVS Caremark: Removed Zepbound from standard formulary effective July 1, 2025

UK professional guidance has specifically discussed incretin-based therapies in women using hormone therapy, highlighting the need to consider bleeding evaluation and medication interactions/symptom interpretation in practice